Discoveries in the redox regulation of KRAS

Oncogenic KRAS is one of the most common drivers of human cancer. Despite intense research, no effective therapy to directly inhibit oncogenic KRAS has yet been approved and KRAS mutant tumors remain associated with a poor prognosis. This short review discusses the current knowledge of the redox regulation of RAS and examines the newest findings on cysteine 118 (C118) as a potential novel target for KRAS inhibition.

Automated summary

This review highlights the significance of oncogenic KRAS in human cancer and the lack of approved therapy to inhibit it. The focus is on the redox regulation of RAS and the potential of targeting C118 as a novel approach for KRAS inhibition.